Profile data is unavailable for this security.
About the company
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
- Revenue in EUR (TTM)175.75m
- Net income in EUR19.88m
- Incorporated1986
- Employees500.00
- LocationPharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
- Phone+34 918466000
- Fax+34 918466001
- Websitehttps://www.pharmamar.com/es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayinglong Pharmaceutical Group Co Ltd | 447.62m | 63.87m | 1.43bn | 2.65k | 22.39 | 2.80 | -- | 3.20 | 1.24 | 1.24 | 8.68 | 9.90 | 0.7155 | 7.19 | 15.29 | 1,410,005.00 | 10.61 | 10.77 | 12.88 | 13.35 | 46.05 | 42.40 | 14.83 | 14.39 | 4.29 | -- | 0.0782 | 37.31 | 18.85 | 6.62 | 19.14 | 7.97 | 34.47 | 18.98 |
| North China Pharmaceutical Co Ltd | 1.18bn | 19.90m | 1.43bn | 10.09k | 72.05 | 2.20 | -- | 1.21 | 0.097 | 0.097 | 5.76 | 3.18 | 0.4612 | 2.75 | 4.32 | 980,007.70 | 1.21 | -0.2469 | 2.76 | -0.578 | 30.54 | 33.78 | 2.62 | -0.5243 | 0.5321 | 2.00 | 0.6473 | -- | -2.48 | -2.94 | 2,496.80 | -5.90 | 3.21 | 0.00 |
| Tibet Rhodiola Pharmaceutical Holding Co | 336.67m | 120.53m | 1.44bn | 596.00 | 11.96 | 2.94 | -- | 4.28 | 3.12 | 3.12 | 8.73 | 12.72 | 0.5459 | 1.55 | 6.04 | 4,722,485.00 | 19.63 | 14.99 | 25.87 | 19.30 | 92.88 | 92.11 | 35.96 | 23.95 | 3.72 | -- | 0.1112 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
| Luye Pharma Group Ltd | 724.92m | 56.44m | 1.44bn | 5.15k | 25.55 | 0.8518 | 8.40 | 1.99 | 0.1374 | 0.1374 | 1.76 | 4.12 | 0.22 | 2.32 | 2.78 | 1,288,895.00 | 2.34 | 1.98 | 3.84 | 3.16 | 66.72 | 68.37 | 10.64 | 8.04 | 1.15 | 3.01 | 0.4001 | 0.00 | -1.33 | -0.9503 | -11.40 | -19.50 | -10.95 | -- |
| Chongqing Taiji Industry Group Co Ltd | 1.32bn | -17.42m | 1.44bn | 11.97k | -- | 3.38 | -- | 1.10 | -0.4538 | -0.4538 | 20.65 | 6.40 | 0.7447 | 2.70 | 4.19 | 919,418.60 | -0.8302 | 0.9924 | -2.57 | 3.04 | 32.62 | 43.37 | -1.11 | 1.08 | 0.4531 | 2.22 | 0.6067 | 22.39 | -20.72 | 1.24 | -96.76 | -- | -3.36 | -- |
| FAES Farma SA | 515.51m | 109.27m | 1.45bn | 1.78k | 13.13 | -- | 11.17 | 2.82 | 0.3495 | 0.3495 | 1.65 | -- | -- | -- | -- | 290,429.80 | -- | 13.17 | -- | 15.13 | 66.29 | 64.65 | 21.15 | 20.72 | -- | -- | -- | -- | 9.42 | 6.67 | 21.17 | 11.73 | 13.09 | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 219.44m | 58.69m | 1.47bn | 2.03k | 25.05 | 4.25 | -- | 6.70 | 1.55 | 1.55 | 5.87 | 9.16 | 0.4006 | 1.16 | 4.15 | 904,626.50 | 10.55 | 7.19 | 15.64 | 9.67 | 67.91 | 59.30 | 26.33 | 20.28 | 0.7316 | 23.05 | 0.4204 | 35.89 | 57.21 | 34.33 | 148.19 | 52.76 | 31.58 | -- |
| Pharma Mar SA | 175.75m | 19.88m | 1.48bn | 500.00 | 71.76 | 7.20 | 54.45 | 8.39 | 1.13 | 1.13 | 10.02 | 11.24 | 0.5267 | 0.2089 | 5.52 | 351,494.00 | 5.96 | 18.37 | 8.02 | 25.03 | 94.41 | 94.02 | 11.31 | 29.81 | 2.33 | -- | 0.2052 | -- | 10.56 | 15.30 | 2,197.71 | -- | 31.72 | -- |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 279.06m | 86.39m | 1.48bn | 2.68k | 17.16 | 2.56 | -- | 5.31 | 1.65 | 1.65 | 5.32 | 11.05 | 0.4217 | 2.55 | 8.49 | 870,840.90 | 13.06 | 17.10 | 14.26 | 21.16 | 43.53 | 42.99 | 30.96 | 30.12 | 5.11 | -- | 0.0455 | 24.41 | 17.35 | 1.75 | 36.85 | -2.20 | 35.06 | -- |
| Tarsus Pharmaceuticals Inc | 200.33m | -89.97m | 1.50bn | 323.00 | -- | 5.09 | -- | 7.47 | -2.73 | -2.73 | 6.07 | 8.15 | 0.5498 | 4.86 | 5.06 | 723,448.90 | -24.69 | -33.35 | -29.10 | -37.21 | 92.99 | -- | -44.91 | -125.04 | 5.54 | -- | 0.1737 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Shanghai Yizhong Pharmaceutical Co Ltd | 21.04m | -958.92k | 1.50bn | 65.00 | -- | 8.76 | -- | 71.27 | -0.0382 | -0.0382 | 0.8583 | 6.93 | 0.1141 | 0.5926 | 1.87 | 2,705,569.00 | -0.5202 | 5.44 | -0.5474 | 5.64 | 86.51 | 92.99 | -4.56 | 36.90 | 17.73 | -- | 0.00 | 32.30 | -51.83 | -- | -95.68 | -- | 10.96 | -- |
| Immunocore Holdings PLC - ADR | 285.98m | -18.54m | 1.52bn | 493.00 | -- | 9.36 | -- | 5.32 | -0.4451 | -0.4451 | 6.51 | 3.77 | 0.33 | 0.6045 | 5.52 | 676,634.90 | -2.14 | -17.90 | -2.52 | -23.26 | 99.01 | -- | -6.48 | -53.74 | 6.31 | -- | 0.5085 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
Data as of Jul 15 2025. Currency figures normalised to Pharma Mar SA's reporting currency: Euro EUR
6.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Jul 2025 | 478.61k | 2.63% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 194.00k | 1.07% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 120.12k | 0.66% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 114.71k | 0.63% |
| Jupiter Asset Management Ltd.as of 31 Mar 2025 | 61.13k | 0.34% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 59.48k | 0.33% |
| SSgA Funds Management, Inc.as of 02 Jul 2025 | 56.87k | 0.31% |
| J. Chahine Capital SAas of 31 May 2025 | 48.43k | 0.27% |
| BNP Paribas Asset Management Europe SASas of 01 Jul 2025 | 35.95k | 0.20% |
| DWS Investments (UK) Ltd.as of 03 Jul 2025 | 33.54k | 0.18% |
More ▼
Data from 31 Dec 2024 - 31 May 2025Source: FactSet Research Systems Inc.
